Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
about
Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironmentHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsEmerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancerProgression and metastasis of lung cancerUp-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathwayRegulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells.A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor.Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer.Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells--interplay of ErbB and IGF1 signalling through IGFBP3 regulation.Down-regulation of vascular endothelial growth factor expression by anti-Her2/neu single chain antibodies.Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumabClinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas.HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimersA phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancerA Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.Role of HGF/MET axis in resistance of lung cancer to contemporary management.Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer.Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast CancerTreatment of HER2-positive breast cancer.Trends and Novel Approaches in Neoadjuvant Treatment of Breast Cancer.Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.ZEB1 Upregulates VEGF Expression and Stimulates Angiogenesis in Breast CancerPrognosis Relevance of Serum Cytokines in Pancreatic Cancer.Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast CancerStroma targeting nuclear imaging and radiopharmaceuticals.A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyA functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.Breast tumour angiogenesisThe Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesisAssociation between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer.Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers.Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axisBreast cancer metastasis: issues for the personalization of its prevention and treatment.Trastuzumab in the management of early and advanced stage breast cancer.Current approaches and future directions in the treatment of HER2-positive breast cancer.Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancerSpecific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.The cardiac safety of trastuzumab in the treatment of breast cancer.
P2860
Q24803543-4DA0E5FC-2A8D-41D0-BD19-650818A6CB45Q26777681-1EA52192-52D6-4345-905E-AD2CB294CFD2Q26824799-A671D595-BF79-474F-8597-EBD6FF011B1EQ28066865-BDF8E2F0-7C16-42BE-8CE8-A3F9001B5FEFQ28216853-0A5A57E7-C5A6-43B4-AB90-7003FDDBA9F8Q30486408-DEB25BA5-5F73-40A1-AA99-DC1AD57994EBQ31104595-461B645A-1151-4E90-B9A2-5946630D9519Q33651388-09FCF25A-D03A-4AEF-A2DF-33BECF920E40Q33692428-FED33795-C009-48D7-A52E-65CA336E64B8Q33803966-6A53480D-E4F2-432F-8DA5-11F2E0754876Q33831958-B33AB2E4-E6DB-449E-92DB-FA219CABDB06Q33943812-E2D9AFCA-4A19-4361-BCD6-98B5A199ADF2Q33968465-80666B60-2A1D-4DE7-99B4-D646FF14397EQ34274718-01607F59-7218-429A-87A0-687F4468EC8AQ34978404-B3D28164-5398-445B-84F2-AF94776B7C41Q35001280-9B151EC2-F41D-43DF-BB0A-9DD585AD20F3Q35200337-3B43FD3B-8587-4709-A88A-22AAD46A1BF1Q35653820-D38713FC-07C1-417C-BC95-1F2C4B446AB2Q35684440-0706923C-90F8-4632-95DE-F337D0D9351CQ35740877-F5BF46C0-0414-45C4-B3A0-C72387704D1AQ35789399-78BF19BB-105C-4BA4-9AEB-CD9AEA8223CCQ35913214-0C73C373-B8C7-4C26-AC2D-1B4B02D3A713Q35925156-5D1F6CF6-FC73-46D8-BA02-F8375CD1D584Q35963911-7F3A8FAC-DE21-4F31-B208-2B3A85501CBAQ35977527-D7A6E73D-0DF0-41D6-AD80-CC1A2E2870C7Q35999606-477574A2-FBA9-46A3-933E-C7E1574E07B9Q36095920-E97FCB17-D337-4538-9C39-68F06E655240Q36116250-3223435C-414C-4225-A07C-514E9DD7A4E8Q36195594-D29058AD-C62F-4504-B409-9BEDF7BB839CQ36465291-6CAD190D-AC4C-48E0-8882-592BF0DACDD2Q36601812-60B42932-B2DB-4562-9076-C386817FCC4FQ36616962-6B5D77C8-5548-4905-8576-6AF0694BA42EQ36673732-C3DDE66F-0224-4099-BFDB-54AB82C152D0Q36689047-FFB22584-5E71-4F7B-BFDD-FADCC20F820DQ37218214-1A8E6872-2DC6-4632-858F-0890C2BAC951Q37290613-C4638891-B916-475C-AA6E-8E97478CD945Q37330128-C6E270F6-5C17-4925-8205-C8F547270550Q37355762-5C5DCA0E-299B-4ABB-9C75-0E9E2DEBAAD6Q37375540-D726A013-75F8-4B75-A1DD-4B7A9A104809Q37696505-72008DD7-966F-4637-9A87-E3F5A0DB7F6A
P2860
Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Heregulin selectively upregula ...... s and stimulates angiogenesis.
@en
type
label
Heregulin selectively upregula ...... s and stimulates angiogenesis.
@en
prefLabel
Heregulin selectively upregula ...... s and stimulates angiogenesis.
@en
P2093
P356
P1433
P1476
Heregulin selectively upregula ...... s and stimulates angiogenesis.
@en
P2093
Al Moustafa AE
Alaoui-Jamali MA
P2888
P304
P356
10.1038/SJ.ONC.1203685
P407
P577
2000-07-01T00:00:00Z
P5875
P6179
1018924967